Follow
Fred Saad
Fred Saad
Professor of Urology, Urologic Oncology and Chairman, Deparment of Surgery, University of Montreal
Verified email at umontreal.ca
Title
Cited by
Cited by
Year
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
EMA Tannock IF1, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S ...
N Engl J Med. 351 (15), 1502-12, 2004
7245*2004
Increased survival with enzalutamide in prostate cancer after chemotherapy
HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R De Wit, ...
New England Journal of Medicine 367 (13), 1187-1197, 2012
51892012
Abiraterone and increased survival in metastatic prostate cancer
JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ...
New England Journal of Medicine 364 (21), 1995-2005, 2011
50222011
The immune landscape of cancer
V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...
Immunity 48 (4), 812-830. e14, 2018
44282018
Enzalutamide in metastatic prostate cancer before chemotherapy
TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
New England Journal of Medicine 371 (5), 424-433, 2014
33442014
Abiraterone in metastatic prostate cancer without previous chemotherapy
CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ...
New England Journal of Medicine 368 (2), 138-148, 2013
31992013
The molecular taxonomy of primary prostate cancer
A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ...
Cell 163 (4), 1011-1025, 2015
26062015
An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics
J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ...
Cell 173 (2), 400-416. e11, 2018
25982018
Oncogenic signaling pathways in the cancer genome atlas
F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ...
Cell 173 (2), 321-337. e10, 2018
24572018
Comprehensive characterization of cancer driver genes and mutations
MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ...
Cell 173 (2), 371-385. e18, 2018
21662018
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
CKN Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY ...
N Engl J Med. 377 (4), 352-360, 2017
2109*2017
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
F Saad, DM Gleason, R Murray, S Tchekmedyian, P Venner, L Lacombe, ...
Journal of the National Cancer Institute 94 (19), 1458-1468, 2002
20982002
Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer
KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ...
Cell 173 (2), 291-304. e6, 2018
20312018
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo …
K Fizazi, HI Scher, A Molina, CJ Logothetis, KN Chi, RJ Jones, ...
The lancet oncology 13 (10), 983-992, 2012
16832012
Olaparib for metastatic castration-resistant prostate cancer
J de Bono, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ...
New England Journal of Medicine 382 (22), 2091-2102, 2020
16812020
Machine learning identifies stemness features associated with oncogenic dedifferentiation
TM Malta, A Sokolov, AJ Gentles, T Burzykowski, L Poisson, JN Weinstein, ...
Cell 173 (2), 338-354. e15, 2018
15912018
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall …
CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ...
The Lancet Oncology 16 (2), 152-160, 2015
15482015
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
F Saad, DM Gleason, R Murray, S Tchekmedyian, P Venner, L Lacombe, ...
Journal of the National Cancer Institute 96 (11), 879-882, 2004
14882004
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
O Sartor
NEJM 385 (12), 1091-1103, 2021
14192021
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
MR Smith, B Egerdie, NH Toriz, R Feldman, TLJ Tammela, F Saad, ...
New England Journal of Medicine 361 (8), 745-755, 2009
13792009
The system can't perform the operation now. Try again later.
Articles 1–20